Cargando…

Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a

Pre-treatment HCV quasispecies complexity and diversity may predict response to interferon based anti-viral therapy. The objective of this study was to retrospectively (1) examine temporal changes in quasispecies prior to the start of therapy and (2) investigate extensively quasispecies evolution in...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreau, Isabelle, Levis, John, Crosbie, Orla, Kenny-Walsh, Elizabeth, Fanning, Liam J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2483966/
https://www.ncbi.nlm.nih.gov/pubmed/18613968
http://dx.doi.org/10.1186/1743-422X-5-78
_version_ 1782158077598892032
author Moreau, Isabelle
Levis, John
Crosbie, Orla
Kenny-Walsh, Elizabeth
Fanning, Liam J
author_facet Moreau, Isabelle
Levis, John
Crosbie, Orla
Kenny-Walsh, Elizabeth
Fanning, Liam J
author_sort Moreau, Isabelle
collection PubMed
description Pre-treatment HCV quasispecies complexity and diversity may predict response to interferon based anti-viral therapy. The objective of this study was to retrospectively (1) examine temporal changes in quasispecies prior to the start of therapy and (2) investigate extensively quasispecies evolution in a group of 10 chronically infected patients with genotype 3a, treated with pegylated α2a-Interferon and ribavirin. The degree of sequence heterogeneity within the hypervariable region 1 was assessed by analyzing 20–30 individual clones in serial serum samples. Genetic parameters, including amino acid Shannon entropy, Hamming distance and genetic distance were calculated for each sample. Treatment outcome was divided into (1) sustained virological responders (SVR) and (2) treatment failure (TF). Our results indicate, (1) quasispecies complexity and diversity are lower in the SVR group, (2) quasispecies vary temporally and (3) genetic heterogeneity at baseline can be use to predict treatment outcome. We discuss the results from the perspective of replicative homeostasis.
format Text
id pubmed-2483966
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-24839662008-07-26 Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a Moreau, Isabelle Levis, John Crosbie, Orla Kenny-Walsh, Elizabeth Fanning, Liam J Virol J Research Pre-treatment HCV quasispecies complexity and diversity may predict response to interferon based anti-viral therapy. The objective of this study was to retrospectively (1) examine temporal changes in quasispecies prior to the start of therapy and (2) investigate extensively quasispecies evolution in a group of 10 chronically infected patients with genotype 3a, treated with pegylated α2a-Interferon and ribavirin. The degree of sequence heterogeneity within the hypervariable region 1 was assessed by analyzing 20–30 individual clones in serial serum samples. Genetic parameters, including amino acid Shannon entropy, Hamming distance and genetic distance were calculated for each sample. Treatment outcome was divided into (1) sustained virological responders (SVR) and (2) treatment failure (TF). Our results indicate, (1) quasispecies complexity and diversity are lower in the SVR group, (2) quasispecies vary temporally and (3) genetic heterogeneity at baseline can be use to predict treatment outcome. We discuss the results from the perspective of replicative homeostasis. BioMed Central 2008-07-09 /pmc/articles/PMC2483966/ /pubmed/18613968 http://dx.doi.org/10.1186/1743-422X-5-78 Text en Copyright © 2008 Moreau et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Moreau, Isabelle
Levis, John
Crosbie, Orla
Kenny-Walsh, Elizabeth
Fanning, Liam J
Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a
title Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a
title_full Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a
title_fullStr Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a
title_full_unstemmed Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a
title_short Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a
title_sort correlation between pre-treatment quasispecies complexity and treatment outcome in chronic hcv genotype 3a
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2483966/
https://www.ncbi.nlm.nih.gov/pubmed/18613968
http://dx.doi.org/10.1186/1743-422X-5-78
work_keys_str_mv AT moreauisabelle correlationbetweenpretreatmentquasispeciescomplexityandtreatmentoutcomeinchronichcvgenotype3a
AT levisjohn correlationbetweenpretreatmentquasispeciescomplexityandtreatmentoutcomeinchronichcvgenotype3a
AT crosbieorla correlationbetweenpretreatmentquasispeciescomplexityandtreatmentoutcomeinchronichcvgenotype3a
AT kennywalshelizabeth correlationbetweenpretreatmentquasispeciescomplexityandtreatmentoutcomeinchronichcvgenotype3a
AT fanningliamj correlationbetweenpretreatmentquasispeciescomplexityandtreatmentoutcomeinchronichcvgenotype3a